Document:

Agreement between the registrant and Impinj, Inc., dated June 10, 2005

 Exhibit 10.36 
 CONFIDENTIAL INFORMATION REQUESTED BY ALIEN TECHNOLOGY CORP. 
 FIRST AMENDMENT TO AGREEMENT

 This FIRST AMENDMENT TO AGREEMENT (the “First Amendment”) is made and effective as of September 29, 2005, by and
between Alien Technology Corporation, a Delaware corporation (“Alien”) and Impinj, Inc., a Delaware corporation (“Impinj”) under the following circumstances: 
 A. On June 10, 2005, Alien and Impinj entered into an Agreement (“Agreement”) for the supply of Gen 2 Specification compliant RFID tag
silicon integrated circuits (“Monza”); and 
 B. Alien and Impinj desire to modify the terms of the Agreement on such terms and
conditions as are set forth in this First Amendment. 
 NOW THEREFORE, in consideration of the premises and for other good and valuable
consideration, the receipt and sufficiency of which hereby are expressly acknowledged, the Parties agree as follows: 
 1. Any words with an
initial capitalized letter in this Amendment not defined in this First Amendment shall have the meaning given to such words in the Agreement. Terms defined in this First Amendment that are not defined in the Agreement shall have the meaning given to
such term herein. 
 2. Without waiving rights or obligations under the Agreement, the parties acknowledge that the Product Acceptance Date
is September 29, 2005. Alien shall pay Impinj the Pre-Paid Amount not later than seven (7) days following the effective date of this First Amendment. 
 3. With respect to the Pre-Paid Amount, Impinj’s estimated NRE fees for the development of Monza-FSA, in lieu of the first two sentences of Section 6(e) of the Agreement, will be [***] split into three
categories: 
 (a) Wafer and mask charges ([***]) 
 As a consequence of (a) above, Impinj will incur expenses of approximately [***] for mask charges and to procure the preliminary 6 wafers from 2 separate engineering lots for Impinj evaluation of Monza-FSA.

 (b) Labor charges ([***]) 
 Impinj will use commercially reasonable efforts to keep Labor charges (b, above) less than [***], provided however that the Labor charges to Alien shall in no event exceed [***]. These charges will cover labor hours related to design,
layout, test engineering and evaluation of Monza-FSA. Costs above [***] for (b) above need to be mutually agreed to before being incurred by Impinj. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Delivery of six Monza-FSA wafers to Alien ([***]) 
 Per section 3(c) above, Impinj will make available 6 additional wafers of Monza-FSA to Alien for the purposes of determining suitability for the FSA
process. 
 All other Monza-FSA wafers purchased by Alien will not be considered as a portion of the NRE fees (defined in sections (5.(a).iii.1) and
(6.e) of the Agreement. 
 Impinj will meet the following schedule: 
  

					
	  	  	 Milestone
	  	 Date

	 (i)
	  	 Start Monza 1A layout for FSA
	  	 [***] (target date).

	 (ii)
	  	 Tapeout of Monza-FSA
	  	 [***] (target date).

	 (iii)
	  	 Engineering silicon samples
	  	 [***] (target date).

	 (iv)
	  	 Production
	  	 UponAlien acceptance & release, but not later than [***].

 All of the provisions of the Agreement not specifically amended as set forth in this First
Amendment remain in full force and effect. Except as expressly set forth herein, nothing in this First Amendment shall be construed to constitute a waiver by Impinj or Alien of any provision of the Agreement. This First Amendment along with the
Agreement (including the exhibits thereto) contain the entire agreement between the parties with respect to the subject matter of this First Amendment and the Agreement and supersede all previous communications, representations, understandings and
agreements, either oral or written, between the parties with respect to said subject matter. This First Amendment may be executed in counterparts, each of which when so executed will be deemed an original and such counterparts together will
constitute one and the same agreement. 
  

									
	Alien Technology Corporation	 		 	Impinj, Inc.
					
	 By: 
	 	 /s/ John Payne
	 		 	 By: 
	 	 /s/ William T. Colleran

			
	 Print Name:  John Payne
	 		 	 Print Name:  William T. Colleran

			
	 Title:  Chief Operating Officer
	 		 	 Title:  President

  

 2 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Agreement 
 This agreement (the “Agreement”) is entered into as of June 10, 2005 (the “Effective Date”) by and between Impinj, Inc., a Delaware corporation with its principal place of business
located at 501 N. 34th Street, Suite 100, Seattle, WA 98103 (“Impinj”), and Alien Technology Corporation, a Delaware corporation with its principal place of business located at 18220 Butterfield Blvd., Morgan Hill, CA 95037
(“Alien”) (each a “party” and collectively the “parties”). 
 Recitals 

Impinj desires to sell to Alien, and Alien desires to purchase from Impinj, Impinj’s initial implementation of EPCglobal’s Gen 2
Specification compliant RFID tag silicon integrated circuit (“Monza”) and/or certain future versions of Monza, as set forth below; 
 The parties desire that Alien place an immediate order of 24 risk wafers of Monza, Alien commit to a prepayment in the amount of [***], Alien commit to a minimum purchase amount of [***] units of Product, and that Impinj perform its
obligations and deliver the deliverables required of it hereunder so that Alien may assemble RFID straps, inlay and/or label products using wafers supplied by Impinj hereunder, all as set forth below; 
 In consideration of the mutual promises contained herein, the parties agree as follows: 
 Agreement 
  

	1.	Definitions. The following terms shall have the following meanings: 

 “Confidential Information” means any information disclosed by one party to the other in connection with the performance of this Agreement, including Intellectual Property and other information that
relates to the disclosing party’s products, designs, business plans, business opportunities, finances, research, development, know-how, personnel, or third-party confidential information disclosed to the receiving party by the disclosing party
in any form whatsoever (including, but limited to, disclosure made in writing, orally or in the form of samples, models, computer programs or otherwise), and the terms and conditions of this Agreement, provided that such information is at the time
of disclosure either designated as “confidential”, “proprietary,” or similar legend or reasonably should be known to the receiving party to be confidential. Confidential Information does and will not include material that:
(i) is now or subsequently becomes generally available to the public or is disclosed to third parties without restriction on its use or disclosure; (ii) the receiving party had rightfully in its possession prior to disclosure by the
disclosing party; (iii) is developed independently by or for the receiving party without the use of any Confidential Information of the disclosing party; (iv) the receiving party rightfully obtains without restriction from a third party
who has the right to transfer or disclose it; or (v) is disclosed with the prior written approval of the disclosing party. 
  

 3 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Assembled Parts” means a Product included as a component of an Alien strap, inlay
or finished label that is intended for shipment to Alien’s customer. 
 “EPCglobal” means EPCglobal Inc., and its
successors and assigns. 
 “Epidemic Failure” means a series of failures (i) indicating a common or systemic Product
failure related to the same or similar root cause, (ii) equal to or in excess of [***] of the total number of Assembled Parts during any rolling [***] month period; and (iii) resulting in the failure of Products to meet the Limited
Product Warranty, (iv) during the Limited Warranty Period. 
 “FSA Intellectual Property” has the meaning set forth in
Section 2(c). 
 “Gen2 Specification” means any Class 1, Generation 2 specification that is ratified by
EPCglobal’s Board of Governors. 
 “Intellectual Property” means all circuit designs, hardware description language
coding, software (including firmware), simulation models, schematics, layout topologies, cells, libraries, data, formulas, designs, software, other original works of authorship, applications, processes, products, know-how, techniques, programs,
improvements, test protocols, test structures, characterization and test results, methods and patterns, specifications and other technical information, whether or not patentable or otherwise protectable. 
 “Intellectual Property Rights” means all copyright rights, patent rights (including reissues, divisions, renewals, extensions,
provisionals, continuations and continuations-in-part thereof, and equivalent or similar rights anywhere in the world in inventions and discoveries), trademark rights, trade secret rights, moral rights, rights of publicity, authors’ rights,
semiconductor mask work rights, contract and licensing rights, goodwill and all other intellectual property rights as may exist now and/or hereafter come into existence and all applications therefor and registrations, renewals and extensions
thereof, regardless of whether such rights arise under the law of the United States or any other state, country, jurisdiction or international treaty. 
 “KGD” shall mean the known good die on a Product wafer. For Monza and Monza-2 wafers, the number of known good die will be determined as measured by Impinj during Testing of the Product in wafer form.
For Monza-FSA, the number of known good die will be determined by Impinj via the Sample Testing Procedure. 
 “Limited Product
Warranty” shall have the meaning set forth in Section 9(a)(i). 
 “Limited Warranty Period” shall mean
one (1) year from the date that Products are received by Alien. 
 “Minimum Purchase Amount” shall have the meaning set
forth in Section 4(a). 
 “Monza” shall have the meaning set forth in the Recitals. 
  

 4 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 “Monza Specifications” shall have the meaning set forth in
Section 2(a)(i). 
 “Monza-2” shall have the meaning set forth in Section 2(b). 
 “Monza-2 Specifications” shall have the meaning set forth in Section 2(b). 
 “Monza-FSA” shall have the meaning set forth in Section 2(c). 
 “Monza-FSA Specifications” shall have the meaning set forth in Section 2(c). 
 “NRE” means non-recurring engineering. 
 “Order” shall have the meaning set forth in Section 8(a)(i). 
 “Pre-Paid Amount” shall have the meaning set forth in Section 5(a)(i). 
 “Product”
means Monza, Monza-2, and/or Monza-FSA, as applicable. 
 “Product Acceptance” shall have the meaning set forth in
Section 2(a). 
 “Product Acceptance Date” shall have the meaning set forth in Section 2(a).

 “Specifications” means either the Monza Specifications, Monza-2 Specifications or Monza-FSA Specifications. 

“Risk Wafers” shall have the meaning set forth in Section 3(a). 
 “Sample Testing Procedure” shall mean a process by which Impinj tests up to 200 die on a Monza-FSA wafer and extrapolates to determine
the number of good die on the entire wafer. A detailed definition of this process will be determined mutually at a later date. 
 “Testing” means those test procedures for Products as set forth in Exhibit B. 
 “Walmart” means
Wal-Mart Stores, Inc. 
  

	2.	Evaluation, Development and Product Specifications. 

 (a) Monza. 
 (i) Specifications. The Monza Specifications, including performance specifications,
current as of the Effective Date are set forth in Impinj’s documentation provided to Alien on or about May 18, 2005 (“Monza Specifications”), and attached hereto as Exhibit A. Monza shall perform in accordance with the
performance specifications included as part of the Monza Specifications. Impinj shall update the Monza Specifications from time to time as conditions warrant and to conform with the updates to the Gen2 Specification with the consent of 

  

 5 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Alien, which consent shall not be unreasonably withheld. When used in this Agreement, Monza Specifications refers to the most recent version agreed to by the
parties. 
 (ii) Product Acceptance. Impinj shall submit Monza to certify its compliance with the Gen2 Specification
according to procedures established by EPCglobal and, at its sole cost and expense, Impinj shall revise and resubmit Monza until such time as EPCglobal or one of its designated third party compliance laboratories certifies Monza as compliant with
the Gen2 Specification; provided however, that if after three (3) such submissions, Monza is not certified, the parties will discuss in good faith next steps to obtain certification for Monza, if obtainable, and Impinj shall not have further
obligation to submit Monza to EPCglobal. Any version of Monza that: (1) is certified by EPCglobal or one of its designated third party compliance laboratories as compliant with a Gen2 Specification; (2) implements a version of the Gen2
Specification that Walmart indicates it will accept; and (3) materially complies with the Monza Specifications, shall be deemed accepted hereunder (the “Product Acceptance”). The latter of the dates that: (1) a version of Monza
is certified as compliant with a Gen2 Specification in accordance with above; (2) Walmart first publicizes or otherwise indicates its intent to accept products compliant with such version of the Gen2 Specification; and (3) Testing for
Monza is completed, and Monza materially complies with the Monza Specifications, shall be the “Product Acceptance Date.” If, for any reason, Walmart publicizes or otherwise indicates its intent to no longer accept the version of the Gen2
Specification with which the Monza Specification is compliant, then (i) Impinj shall immediately notify Alien, (ii) Alien shall have the right to cancel any outstanding Orders in accordance with this Agreement, and thereafter
(iii) Alien shall have the right to terminate this Agreement. 
 (iii) Samples of Monza-Based Straps or Inlays.
Within eight (8) weeks of delivery of the first Risk Wafer (as described in Section 3(b)), Alien shall produce and deliver to Impinj at least one thousand (1,000) known good straps or inlays incorporating Monza die from such
Risk Wafer. Each party shall evaluate the performance of such straps or inlays within two (2) weeks of delivery to Impinj. The parties shall share the results of such performance evaluation. Such results shall be deemed Confidential Information
of both parties. Each party agrees not to distribute to any third party or otherwise allow any third party to sample any Alien-assembled strap or inlay incorporating any Monza die arising from the first Risk Wafer (as described in
Section 3(b)) without the prior written consent of the other party. 
 (b) Monza-2. Impinj may develop a cost-reduced
version of Monza (“Monza-2”) provided that Impinj shall have no obligation to develop, release or sell Monza-2. If Impinj decides to develop, release or sell Monza-2, the specifications for Monza-2 shall be as set forth by Impinj
(“Monza-2 Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience gained with Monza wafers. If it is evident that typical performance of
Monza is better than is reflected in the Specification, the acceptance specification for Monza-2 will be shifted toward more sensitivity, by mutual agreement of the parties. Provided that Alien is not in breach of this Agreement, Impinj will provide
Alien with early access and beta versions of Monza-2 and metal variants of Monza-2 no later than it provides access to other Impinj customers. 
  

 6 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) Monza-FSA. Following receipt of the applicable NRE fees set forth herein, Impinj agrees to
use commercially reasonable efforts to develop a customized Monza product that is compatible with Alien’s patented “Fluidic Self Assembly” process (“Monza-FSA”); provided that Alien provides such information and
assistance as is reasonably requested by Impinj. Alien acknowledges and agrees that such development efforts may be unsuccessful and Impinj shall have no obligation to release or sell Monza-FSA. The specifications of the Monza-FSA (if and when
available) shall be as mutually agreed to by the parties in writing (“Monza-FSA Specifications”). The sensitivity acceptance specification defined in Note 4 of the Monza Specification shall be reevaluated in light of the experience
gained with Monza wafers. If it is evident that typical performance of Monza is higher than is reflected in the Specification, the acceptance specification for Monza-FSA will be shifted toward more sensitivity, by mutual agreement of the parties.
Monza-FSA Specifications may include a test structure that will allow Impinj to use its standard test procedures to determine wafer yields on a sampling basis (i.e., wafers to include test structures built into reticles for Impinj to test prior to
sending to Alien). For those portions of the Monza-FSA that are Alien’s Intellectual Property as defined under Section 10(c) (“FSA Intellectual Property”), such FSA Intellectual Property shall be and remain Alien
Confidential Information. Impinj shall have no right to sell, license, transfer or otherwise distribute the FSA Intellectual Property. 
  

	3.	Risk Wafers. 

 (a) Definition. All orders by
Alien or deliveries by Impinj of Monza wafers shall be deemed “Risk Wafers” until Impinj provides written notice that it is releasing Monza into production. 
 (b) Initial Delivery of Risk Wafer. On or prior to June 30, 2005, Impinj shall deliver to Alien without charge or other expense one
(1) Risk Wafer along with one thousand (1,000) assembled Monza tags and one hundred (100) Monza die in waffle pack. 
 (c)
First Order and Delivery of Risk Wafers. On May 20, 2005, Alien issued a non-cancelable Order for [***] Risk Wafers (“Risk Wafer Order”). Impinj acknowledges receipt of the Risk Wafer Order. The schedule delivery date of
such Risk Wafers shall be twelve (12) weeks from May 20, 2005. For purposes of clarification, the single Risk Wafer delivered to Alien pursuant to Section 3(b) shall not be included within such [***] Risk Wafer Order. Except
for the restrictions of Section 2(a)(iii), nothing contained herein shall prevent Alien from selling or otherwise distributing straps, inlays, or labels built using the Risk Wafers purchased under this Section 3(c) to Alien’s
resellers and end customers. 
 (d) AS-IS Without Warranty. Alien acknowledges and agrees that all Risk Wafers are sold “AS
IS” without any warranty of any kind. 
  

	4.	Minimum Purchase Requirements. 

 (a) Total
Minimum Purchase Amount. During the term of this Agreement, subject to Impinj’s compliance with its material obligations and liabilities hereunder, Alien shall purchase a minimum of [***] units of Product (“Minimum Purchase
Amount”). Such minimum may 

  

 7 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
comprise any combination of units of Monza, Monza-2 and Monza-FSA, subject to Alien’s discretion and, in the case of Monza-2 and Monza-FSA, availability
from Impinj. Alien acknowledges that the Risk Wafer specified in Section 3(b) shall not be counted towards the Minimum Purchase Amount. Risk Wafers specified in Section 3(c) shall be counted towards the Minimum Purchase
Amount. In addition, the parties agree that the determination of the number of units of Product on a single wafer for purposes of accounting for the Minimum Purchase Amount shall be the number of KGD on that wafer. 
 (b) Timing of Minimum Purchase Amount. 
 (i) Subject to Section 4(d), Alien shall issue non-cancelable Orders for the Minimum Purchase Amount by [***] and receive delivery of the same by [***]. 
 (ii) Subject to Section 4(d), Alien shall issue non-cancelable Orders and receive delivery for: (1) at least [***] of
Product by [***]; and (2) at least an additional [***] by [***]. Alien acknowledges and agrees that it shall place such Orders prior to the applicable Lead Times. 
 (c) Order Increments. Alien acknowledges and agrees that Impinj delivers Monza and Monza-2 in whole wafer increments. Alien acknowledges and agrees that the yield of a particular wafer may vary and as such, the
number of KGD on each wafer may vary. As such, in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order up to an additional [***] units of Monza or Monza-2 Product. Alien acknowledges and agrees that Impinj delivers
Monza-FSA in whole lot increments, consisting of twenty-five (25) wafers. Alien acknowledges and agrees that the yield of a particular lot may vary. As such, in order to meet Alien’s Minimum Purchase Amount, Alien may be required to order
up to an additional twenty-five (25) wafer lot of Monza-FSA. 
 (d) Timing of Product Acceptance. In the event that the Product
Acceptance Date does not occur by September 1, 2005, the delivery dates set forth in Section 4(b) shall be extended one day for each day that the Product Acceptance Date is after September 1, 2005. For purpose of illustration,
if the Product Acceptance Date occurs on September 21, 2005, each of the delivery dates set forth in Section 4(b) shall be extended by twenty (20) days. 
  

	5.	Payments. 

 (a) Prepayments. 
 (i) Amount. Subject to Section 5(a)(ii), Alien shall pay Impinj a non-refundable [***] (“Pre-Paid Amount”) as
a prepayment for certain amounts due under this Agreement. 
 (ii) Timing. Alien shall pay Impinj the Pre-Paid Amount
the later of (1) seven (7) days following the Product Acceptance Date and (2) September 1, 2005; provided however that in the event the Product Acceptance date does not occur by December 31, 2005 and Alien 

  

 8 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
terminates this Agreement pursuant to Section 13(b)(i), Alien shall have no obligation to pay the Pre-Paid Amount. 
 (iii) Allocation. 
 (1) NRE Fees for Development of Monza-FSA. The parties agree that the Pre-Paid Amount shall be used to fully satisfy the NRE fees due to Impinj for the development of Monza-FSA pursuant to
Section 6(e). 
 (2) Credit for Product Purchases In Excess of [***]. The parties agree that the amount of
the Pre-Paid Amount remaining after Alien has paid Impinj the applicable NRE fees due under Section 6(e) (i.e., [***] if the NRE fees are [***] or [***] if the NRE fees are [***]) (the “Credit Amount”) may be used as a
credit against purchases of production orders of (i) Monza or Monza-2 versions of the Product in excess of the [***] of production versions of Product ordered by Alien pursuant to this Agreement, and (ii) Monza-FSA versions of the Product
commencing on the initial production versions of Product ordered by Alien pursuant to this Agreement. The Credit Amount shall be credited against such purchases at a rate of [***]. The Credit Amount must be used by Alien within six (6) months
of the date Alien purchases its forty millionth unit of production Product. If Alien fails to fully use the Credit Amount by such date, Alien shall not be entitled to the benefit of any remaining amount of the Credit Amount. 
 (b) Payment Terms. Alien shall pay Impinj all invoiced amounts net thirty (30) days from the date of Alien’s receipt of each invoice.
All payments due under this Agreement shall be made in US dollars by check or bank wire transfer to an account designated by Impinj. Without prejudice to any other remedy, in the event any amount is not paid by Alien when due, following ten
(10) business days written notice by Impinj to Alien during such time Alien having the right to cure, Impinj may assess, and Alien agrees to pay, a late charge of the lesser of one and one quarter percent (1.25%) per month or the maximum
percentage allowed by law for each month or portion thereof that the amount is past due. 
 (c) Taxes. Amounts payable to Impinj under
this Agreement are payable in full to Impinj without deduction and are net of taxes (including any sales, use, excise, ad valorem, property, withholding, value added tax, or other tax and any income tax withheld at source), tariff, duty or
assessment levied or imposed by any government authority that may be applicable to the transactions contemplated by this Agreement based on delivery terms set forth in Section 8(b), exclusive of taxes based on Impinj’s net income
and any taxes (including those set forth above in this paragraph) prior to delivery to Alien. 
  

	6.	Fees and Prices. 

 (a) Risk Wafers. The price
of each Risk Wafer ordered by Alien pursuant to Section 3(c) shall be [***]. The total purchase price of the first order of Risk Wafers shall be [***]. Additional risk wafers ordered (excluding Section 6(c)) will be priced in accordance
with Section 6(b). 
  

 9 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (b) Prices of Product Purchased to Meet the Minimum Purchase Amount. 
 (i) Monza. For Monza Product that is purchased to meet the Minimum Purchase Amount, the unit price for each Monza KGD shall be
[***] subject to offset by the Credit Amount applicable to each unit. For purposes of clarification, Alien shall only be required to pay for each KGD on Monza wafers. As such, any non-KGD on any Monza wafer may not be used to satisfy any part of the
Minimum Purchase Amount. 
 (ii) Monza-2. For Monza-2 Product (if and when available) that is purchased to meet the
Minimum Purchase Amount, the unit price for each Monza-2 KGD shall be [***] multiplied by the ratio of the number of die on a Monza wafer over the number of die on a Monza-2 wafer (unless a lower unit price is mutually agreed by the parties in
writing) subject to offset by the Credit Amount applicable to each unit. For purposes of illustration, if the number of die on a Monza-2 wafer is [***] larger than the number of die on a Monza wafer, the unit price for each Monza-2 KGD shall be
[***]. For purposes of clarification, Alien shall only be required to pay for each KGD on Monza-2 wafers. As such, any non-KGD on any Monza-2 wafer may not be used to satisfy any part of the Minimum Purchase Amount. 
 (iii) Monza-FSA. For Monza-FSA Product (if and when available) that is purchased to meet the Minimum Purchase Amount, the unit
price for each Monza-FSA wafer shall be [***] (“MW Price”) subject to certain price adjustments as described below in this Section 6(b)(iii); provided, that Monza-FSA is available from Impinj in production quantities prior to [***].
Additionally, in the event Monza-FSA wafer yields are less than the Minimum FSA Yield, then the MW Price shall be decreased to reflect the actual percentage yield below the Minimum FSA Yield. Commencing with Impinj’s first shipment of
production versions of Monza-FSA, the Minimum FSA Yield shall be [***], and shall increase by [***] for each Monza-FSA lot accepted by Alien thereafter up to a maximum of [***]. For Monza-FSA wafers whose yield is lower than the Minimum FSA Yield,
Impinj will offer a price discount from the MW Price equal to the percentage difference between the actual yield of the wafer and the Minimum FSA Yield. For purposes of clarification, in the event a wafer from the third lot of Monza-FSA shipped by
Impinj has a yield of [***], then Alien will be entitled to a [***] discount from the MW Price for that wafer [***]. Monza-FSA wafer yields will be set by the Sample Testing Procedure. 
 (c) Prices of Product Purchased In Excess of the Minimum Purchase Amount. If Alien commits to purchase an annual volume of Products in excess of
fifty million units (in addition to the Minimum Purchase Amount) under the terms and conditions of this Agreement, Impinj agrees that the purchase prices for such Products shall be no higher than the prices set forth in Section 6(b).

 (d) [***]. During the term of this Agreement, Impinj agrees that if Impinj sells Products to a third party [***], taken as a whole,
that are [***], this Agreement and any outstanding Orders shall be deemed [***]. Impinj warrants that the terms and conditions reflected herein [***]. 
 (e) NRE Fees for Development of Monza-FSA. Alien shall pay Impinj [***] as NRE fees in consideration of Impinj’s development efforts set forth in 

  

 10 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
Section 2(c). The NRE fees may be increased to [***] if mutually agreed to in writing by the parties. For purposes of clarification, the NRE fee
in this Section 6(e) is the same (and not in addition to) the NRE referenced elsewhere in this Agreement. 
  

	7.	Forecasts; Lead Times; Delivery Requirements. 

 (a)
Forecasts. Within the first ten (10) days of the beginning of each calendar month, Alien shall provide Impinj with a written twelve (12) month rolling forecast, updated monthly setting forth Alien’s estimated monthly
requirements for Products. The first [***] of such forecast shall be binding (subject to rescheduling, cancellation and other provisions hereof), and Alien shall issue non-cancelable Orders within the applicable Lead Times to cover such period. The
remaining [***] of such forecast shall be non-binding; provided, however, Alien may, in its discretion, issue non-cancelable Orders to cover such period. 
 (b) Lead Times. Alien acknowledges that the lead times for the Products in production quantities (“Lead Times”) are currently [***] for Monza and expected to be [***] for Monza-2 (if and when
available) and Monza-FSA (if and when available). Lead Times are associated with wafer processing alone and do not contemplate back end processing functions such as bumping, thinning, scribing, etc. Impinj shall provide Alien prompt written notice
if the Lead Times change. 
 (c) Delivery Requirements. 
 (i) Order Increments. Alien acknowledges and agrees that delivery of all Products shall be in accordance with Section 4(c).

 (ii) Yield of Product Wafers. Impinj acknowledges and agrees that it will not ship Monza or Monza-2 wafers to Alien
that have a yield less than [***], except as may be agreed upon by the parties in writing with price reductions as set forth below. Impinj acknowledges and agrees that it will not ship Monza-FSA wafers to Alien that have a yield less than [***],
except as may be agreed upon by the parties in writing with appropriate price reductions as set forth in Section 6(b)(iii), such yield to be determined in a manner to be mutually agreed to by the parties. For Monza-FSA, if Impinj fails to
deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer those wafers for sale to Alien with appropriate price reductions as set forth in
Section 6(b)(iii). For Monza and Monza-2, if Impinj fails to deliver an Order within four (4) days of the scheduled delivery date, and Impinj has inventory of wafers with yield less than [***], Impinj will offer a price discount equal to
the percentage difference between the actual yield of the wafer and [***]. For example, if Impinj sells a wafer to Alien with [***] yield, Alien will be entitled to a [***] discount on the KGD price which has been set in accordance with
Section 6(b). 
 (iii) Form of Monza and Monza-2 Wafers. The production versions of Monza and Monza-2 wafers
delivered to Alien shall not be bumped, thinned or otherwise post-processed. Such wafers shall be initialized (i.e., Impinj will program a valid electronic product 

  

 11 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
code into the appropriate 96-bit memory field of Monza or Monza-2 die) and provided with wafer maps that identify the KGD. 
 (iv) Form of Monza-FSA Wafers. The production versions of Monza-FSA wafers delivered to Alien shall pass standard process control
monitor (“PCM”) tests at Impinj’s foundry and such additional testing and initialization processes as agreed by the parties in the course of developing Monza-FSA. Impinj shall, at a minimum, sample test such wafers but Impinj shall
not be required to bump, thin or otherwise post-process such wafers. Any additional testing or initialization procedures shall be as mutually agreed in writing during the development of Monza-FSA. 
 (v) Performance of Monza and Monza-2 wafers. The wafers that Impinj provides to Alien will have no less sensitivity than those it
sells to others or uses for its own production. 
  

	8.	Order Process; Shipping and Title; Acceptance of Shipments. 

 (a) Order Process. 
 (i) All purchases and sales between Impinj and Alien hereunder shall be initiated by
Alien’s issuance of written purchase orders (“Orders”) to Impinj. All Orders shall include the following: (1) purchase order number; (2) Product number, description and price (by line item); (3) billing address;
(4) shipping address; (5) requested shipment date; (6) authorized signature; and (7) such other information as Impinj may reasonably request. 
 (ii) Impinj agrees to acknowledge Alien’s Orders in writing, or electronically where an electronic data interchange procedure has
been agreed to by the parties, within five (5) working days of receipt. If Impinj is unable to accept any purchase order, Impinj shall give Alien a written explanation. Impinj may not reject or amend any Order that conforms to the terms and
conditions of this Agreement, unless such Order is required to be reduced by allocation under Section 8(b)(iii). 
 (iii)
This Agreement shall govern all orders of Products by Alien. No terms on Orders, invoices or like documents by either party shall serve to alter or add to the terms of this Agreement unless agreed to and signed by both parties in writing.

 (iv) Without Impinj’s prior written consent and except as provided expressly herein, Alien shall have no right to make
any modifications or additions to any Order that has been accepted by Impinj. 
 (v) No later than sixty (60) days prior
to the shipping date, Alien may reschedule any Order for delivery up to thirty (30) days after the original shipping date without charge or penalty. Less than sixty (60) days prior to the shipping date, Alien may only reschedule an Order
with the consent of Impinj. 
  

 12 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (vi) Alien may cancel an Order at any time upon written notice to Impinj; provided,
however, that Alien pays to Impinj the amounts described in this section. Alien will be liable to pay to Impinj any penalties or cancellation fees charged to Impinj by Impinj’s suppliers as a direct consequence of Alien’s cancellation of
the Purchase Order, less any amounts charged for materials that are refundable (collectively, the “Cancellation Fee”). Notwithstanding the foregoing, unless expressly agreed to the contrary in writing by the parties at the time that the
Order is accepted, the Cancellation Fee may not exceed the total invoice value of the Order. Impinj will use its commercially reasonable efforts to minimize, and will perform any commercially reasonable acts necessary to mitigate, any applicable
Cancellation Fees. Upon receipt of notice of cancellation, Impinj will notify Alien within ten (10) business days of the precise amount of the Cancellation Fee, and Alien will have the right to either (1) withdraw its notice of
cancellation and require Impinj to continue to fulfill the Purchase Order; or (2) confirm the cancellation and pay the Cancellation Fee. Failure by Alien to notify Impinj of withdrawal of its notice of cancellation within five (5) business
days after receiving from Impinj the precise amount of the Cancellation Fee will be deemed confirmation of cancellation by Alien. Upon confirmation of any cancellation and receipt from Impinj of an invoice for a Cancellation Fee, Alien will pay the
full Cancellation Fee to Impinj in accordance with the terms of Section 5(b). Notwithstanding the foregoing, Alien may cancel any Order without the obligation to pay any cancellation fee if Impinj fails to deliver Products within thirty
(30) days after the scheduled shipping date. Except as set forth in Section 8(b)(ii), Orders cancelled prior to shipment will not apply towards the Minimum Purchase Amount. 
 (vii) In the event of a suspected Epidemic Failure, Alien shall promptly notify Impinj, and shall provide the following information, if
known and as may then exist: a description of the defect, and the suspected lot numbers, serial numbers or other identifiers, and delivery dates of the defective Products. Alien shall also make available to Impinj samples of the defective Products
for testing and analysis. Within five (5) business days of receipt of notice from Alien, Impinj shall provide its preliminary findings regarding the cause of the failures. Thereafter, Impinj shall promptly provide the results of its root cause
corrective analysis, its proposed plan for the identification of and the repair or replacement of the affected Products, and such other appropriate or desirable information as Alien may reasonably request. The parties shall also cooperate to
expeditiously devise and implement a corrective action program which identifies the defective units for repair or replacement, and which minimizes disruption to Alien’s customers. 
 (b) Shipping and Title. Delivery is FOB Impinj’s facilities (currently in Orange County, CA) (the “Delivery Point”). Title
to, and risk of loss of, the Products shall pass to Alien upon delivery by Impinj to Alien’s designated carrier at the Delivery Point. 
 (i) Impinj will handle and pack all Products so as to protect the Products from loss or damage in transit, in a manner consistent with standard commercial practice and approved by Alien. Subject to Sections 8(b)(ii)
and 8(b)(iii) below, Impinj will endeavor to ship the Impinj Products on or before the shipping date. 
 (ii) In the event of
any delays that cause the shipment to ship four (4) days or more after the scheduled shipping date, and without limiting Alien’s other rights and remedies 

  

 13 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
hereunder, Impinj shall immediately notify Alien of such delay and shall use its commercially reasonable efforts to remedy such delay immediately. In the
event of such delay, Alien may cancel the Order; provided however that the KGD for such shipment shall apply to the Minimum Purchase Amount (or in the event the KGD for such shipment is not known, then the amount attributable to the Minimum Purchase
Amount shall be an amount equal to the average KGD determined over the most recent wafer lot received by Alien). If not cancelled by Alien, Impinj shall use expedited means to ship the Products, at its own expense, to minimize any further delay.

 (iii) If a supplier to Impinj has inadequate capacity to timely fulfill both Alien’s Orders for Products and
Impinj’s other requirements for Impinj Products (including Impinj’s own use of Products), then, without limiting any of Alien’s other rights and remedies, Impinj will allocate the available capacity in a manner that proportionally
reflects Alien’s orders for Products during the previous ninety (90) days. For example, if during the previous ninety days, Alien accounted for sixty percent (60%) of the total production of Impinj Products, then in the event of
inadequate supplier capacity, Impinj will allocate sixty percent (60%) of the available capacity to meet Alien’s requirements for Products. Impinj will work with Alien in good faith to resolve any customer difficulties that may arise
during a period of inadequate capacity, and the parties may mutually agree upon an allocation formula that differs from that set forth above in order to meet urgent Alien requirements. 
 (iv) Impinj will obtain the written consent of Alien prior to implementing any changes to the form, fit, or function of the Products,
which consent may be withheld by Alien in its sole discretion. If Alien elects to withhold such consent, Impinj may implement such changes, but will continue to make available the unchanged variants of the Products to Alien. 
 (c) Acceptance of Shipments. Alien shall give notice to Impinj (and the carrier where appropriate) of discrepancies between Product ordered and
delivered, and of damage to the Product within eleven (11) business days of delivery to the Delivery Point. Lacking such notice, Alien shall be deemed to have received the Product as invoiced, provided however that receipt shall not mean
Acceptance. Alien shall accept (“Acceptance” or “Accepted”) or reject Products included in each shipment within sixty (60) days from delivery. If Alien fails to notify Impinj in writing of its rejection and the reasons
thereof within such time period, Alien will be deemed to have Accepted such shipment. Product may be returned to Impinj only after prior notification and subsequent authorization upon receipt of a return material authorization number issued by
Impinj, provided however that the Acceptance period shall be extended on a day by day basis to the extent Impinj fails to timely provide return authorization. No credit allowances for defective Product will be made or replacements therefore shipped
until Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting, assembly process, post-processing of any Product after delivery (including without limitation
Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper testing that was not authorized or directed by Impinj. Acceptance of Product shall not modify or
otherwise change the applicable Product warranties, and Acceptance shall not constitute a waiver of such Product warranties. 
  

 14 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	9.	Limited Product Warranty. 

 (a) Limited Product
Warranty. Following release of Products into production, Impinj warrants as follows: 
 (i) that such Products supplied to Alien hereunder
shall materially conform to the applicable Specifications of such Product and shall be free from defects in materials and workmanship, (the “Limited Product Warranty”) during the Limited Warranty Period. For purposes of
clarification, the foregoing Limited Product Warranty shall not be applied to any Risk Wafers, engineering wafers or any Products labeled as beta or evaluation versions; 
 (ii) that Products will be new, and free and clear of all liens, encumbrances, security interests, and other claims; 
 (iii) that to Impinj’s knowledge, the Products will not infringe or misappropriate any Intellectual Property Rights of any third party; and 
 (iv) that Impinj has the right and power to enter into this Agreement and grant to Alien the rights set forth herein. 
 (b) Alien’s sole remedy in relation to the warranties under Section 9(a) shall be that: Impinj shall replace, refund or credit, at Impinj’s sole discretion, Alien’s account for any such
Products which are returned by Alien during the warranty period set forth above, (provided that for the last Order under this Agreement, if such Products cannot be replaced, Impinj shall refund amounts to Alien) provided that: 
 (i) Impinj is promptly notified in writing upon discovery by Alien that such Products failed to conform to this Agreement with an explanation of any
alleged deficiencies, 
 (ii) if: 
 (x) still in Alien’s custody then Impinj may require that Alien return such Product, at Impinj’s request; or 
 (y) not
still in Alien’s custody but provided that Alien has agreed to repair, replace or provide a refund/credit to Alien’s customer, then Alien shall have no obligation to return Product outside its custody, and 
 (iii) Impinj’s examination of the Products shall disclose that such alleged deficiencies actually exist and were not caused by any die cutting,
assembly process, post-processing of any Product after delivery (including without limitation Alien’s “Fluidic Self Assembly” process), accident, misuse, neglect, alteration, improper installation, unauthorized repair or improper
testing, that was not otherwise approved or directed by Impinj. Impinj shall be responsible for all costs associated with shipping replacement Products to Alien (Duty Delivery Paid) Alien’s designated location. 
  

 15 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (c) DISCLAIMER. THE LIMITED WARRANTIES SET FORTH IN THIS SECTION 9 ARE IN LIEU OF
ALL CONDITIONS OR WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO, ANY IMPLIED CONDITION OR WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND OF ANY OTHER WARRANTY OBLIGATION ON THE PART OF IMPINJ.

  

	10.	Restrictions; Intellectual Property Rights. 

 (a)
Restrictions. Alien agrees not to: (i) sell or otherwise distribute to any third party any Product in wafer, die (except as packaged in a strap, inlay, tag, label or similar) or raw silicon form; (ii) use any Monza or Monza-2 die
that is not marked as KGD (and Alien agrees to destroy all such non-KGD die); (iii) reverse engineer or otherwise attempt to gain access to logic, structure or design of any Product; (iv) modify or create derivative works of any Product
(except as part of Alien’s FSA process); (v) use any Product in any products or systems for which errors, bugs or malfunctions could cause personal injury or death, property or environmental damage, including without limitation, medical
life support systems (which for the purposes of this Agreement shall exclude pharmaceutical or hospital patient tracking applications), on-line control of aircraft, air traffic, air navigation or aircraft communications or in the design or operation
of any nuclear facility; or (vi) cause or grant permission to any third party to do any of the foregoing. 
 (b) Monza and
Monza-2. Impinj owns and shall retain all Intellectual Property Rights in and to Monza and Monza-2. Improvements, modifications or enhancements to Intellectual Property shall be as set forth in the Intellectual Property Agreement between the
parties, dated May 5, 2005. 
 (c) Third party Infringement. Impinj shall notify Alien in the event Impinj receives or becomes
aware of any notice of any claim, suit or proceeding alleging that Monza infringes any third party Intellectual Property Rights. Alien shall notify Impinj in the event Alien receives or becomes aware of any notice of any claim, suit or proceeding
alleging that FSA Intellectual Property or Alien’s technology used to assemble Monza chips infringes any third party Intellectual Property Rights. 
 (d) Monza-FSA. Ownership of and licenses to Intellectual Property and Intellectual Property Rights shall be as set forth in the Intellectual Property Agreement between the parties, dated May 5, 2005.

 (e) Reservation of Rights. Each party reserves all rights not expressly granted in this Agreement, and no licenses are granted by
either party to the other party under this Agreement, whether by implication, estoppel or otherwise, except as expressly set forth herein. 
 (f) Covenant of Further Assurances. Each party shall, without demanding any further consideration therefor, at the request and expense of the requesting party take all such actions and execute all such documents as reasonably
requested by the other party, in order to effect the intent of this Section 10. 
  

 16 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	11.	Confidentiality; Press Releases. 

 (a) Duty to
Maintain Confidentiality. Each party agrees to accept Confidential Information from the other party solely for use in connection with performance of its obligations and exercise of its rights granted under this Agreement and that for a period of
five (5) years from the date of disclosure it will hold in strict confidence and not disclose, publish, or disseminate such Confidential Information to anyone other than those of its employees and subcontractors with a need to know and who have
executed appropriate confidentiality agreements, nor use Confidential Information for its own or any third party’s benefit, without the prior written approval of an authorized representative of the originating party. The receiving party will
protect Confidential Information of the disclosing party from disclosure, publication, dissemination and unauthorized use with the same degree of care the receiving party uses to protect its own confidential and proprietary information of similar
nature, but in no event less than a reasonable degree of care. Notwithstanding the foregoing, and subject to the restrictions in Section 2(a)(iii), in no event shall Alien be prevented from distributing information about its products that
include Products purchased hereunder provided that such information does not include Confidential Information of Impinj. 
 (b)
Exceptions. The receiving party may disclose Confidential Information if required by operation of law or any tribunal of competent jurisdiction, provided that it will take reasonable steps to first give the originating party sufficient prior
notice to contest the order to disclose, and must cooperate with the originating party in any efforts by the originating party to obtain a protective order or other confidential treatment. The parties shall have the right to disclose the terms of
this Agreement to attorneys, government agencies, financial advisors and potential investors and acquirers (of the party or the party’s relevant foundry, division, or product line), subject to reasonable confidentiality provisions which are no
less restrictive than those provided for herein. 
 (c) Injunctive Relief. The parties acknowledge that any breach or threatened
breach of the obligations of confidentiality contained in this Section 11 may cause substantial harm to the non-breaching party that may not be reasonably or adequately compensated with monetary damages. Accordingly, in addition to any
other available remedies, the parties recognize each party’s right to seek injunctive relief in connection with such breach or threatened breach. 
 (d) Press Releases. The parties agree to issue two (2) joint press releases upon the completion of the milestones as follows: (1) one press release announcing the sampling of Alien-assembled straps or
inlays incorporating Monza die (as set forth in Section 2(a)(iii)) upon the commencement of such sampling; and (2) one press release announcing the commencement of volume production of Monza upon Alien’s order of the first
production quantities of Monza. Each such press release shall indicate that the silicon is produced by Impinj and the straps and inlays are produced by Alien. 
  

	12.	Indemnification. 

 (a) By Impinj. Impinj
shall indemnify, defend and hold harmless Alien from and against any and all third party claims, actions, losses, liabilities, damages, costs and expenses (including but 

  

 17 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
not limited to reasonable attorneys’ fees and costs) to the extent based on a claim that any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA,
only to the extent that Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights) supplied by Impinj to Alien hereunder constitutes infringement or misappropriation of any third party Intellectual Property
Rights and Alien compliance with Impinj’s specifications. (collectively a “Product IP Claim”). Impinj shall not be obligated to defend or be liable for costs and damages if: (i) the infringement arises out of compliance
with Alien’s specifications or instructions or the FSA Intellectual Property; (ii) the infringement arises from a combination with, an addition to, or a modification of the Products after delivery by Impinj; or (iii) the infringement
arises from use of the Products, or any part thereof, in the practice of a process. Impinj’s obligations hereunder shall not apply to any infringement occurring after (i) Impinj has received notice of such suit or proceeding or other
communication alleging the infringement and (ii) Impinj provides such notice to Alien, unless Impinj gives written permission for such continuing infringement. In the event Impinj provides Alien with such notice, and the infringement does not
arise under conditions described in Section 12(b), Alien shall have the right to terminate this Agreement and any Orders without cost or penalty. 
 If
any infringement by Impinj is alleged prior to completion of delivery of the Products under this Agreement, Impinj may decline to make further shipments without being in breach of this Agreement. 
 Without limiting Impinj’s obligations above, if any Monza, Monza-2 or Monza-FSA (but, in the case of Monza-FSA, only to the extent that Monza or Monza-2, as
applicable, alone would have infringed the same Intellectual Property Rights without the FSA Intellectual Property) supplied by Impinj to Alien hereunder shall be held to directly infringe Intellectual Property Rights, and Alien shall be enjoined
from using the same, Impinj shall (or if Impinj reasonably believes that such an injunction may be issued, Impinj may) use reasonable efforts, at its option and at its expense, (i) to procure for Alien the right to use such products free of any
liability for infringement, or (ii) to replace such products with a noninfringing substitute otherwise complying substantially with all requirements of this Agreement, or if the aforesaid enjoinment is confirmed and neither of the actions under
(i) or (ii) above are available on commercially reasonable terms, to (iii) accept return of such products and refund the purchase price of such returned products. 
 (b) By Alien. Alien shall indemnify, defend and hold harmless Impinj from and against any and all claims, actions, losses, liabilities, damages,
costs and expenses (including but not limited to reasonable attorneys’ fees and costs, but excluding any Product IP Claim) to the extent based on a claim that (i) any strap or inlay product from Alien incorporating any Product (but not if
Monza or Monza-2, as applicable, alone would have infringed the same Intellectual Property Rights without the strap or inlay product from Alien); (ii) Impinj’s compliance with Alien’s specifications; (iii) any combination with,
addition to, or modification of the Products after delivery by Impinj to Alien; or (iv) the FSA Intellectual Property; infringes or misappropriates any third party Intellectual Property Rights. 
 (c) Procedures. All indemnification obligations under this section shall be subject to the following requirements: (i) the indemnified party
shall provide the indemnifying party with 

  

 18 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
prompt written notice of any claim; (ii) the indemnified party shall permit the indemnifying party to assume and solely control the defense or
settlement of any claim (provided, that neither party shall enter into any settlement providing for any restriction on the other party without the other party’s prior written consent, such consent not to be unreasonably withheld);
(iii) the indemnified party shall provide proper and full information and all reasonable assistance to defend or settle any such claim, at the indemnifying party’s request and expense; and (iv) the indemnified party shall not have
compromised or settled any such claim without the indemnifying party’s prior written consent. In addition, the indemnifying party shall not be responsible for any costs, expenses, compromises, or settlements incurred or made by the indemnified
party without the indemnifying party’s prior written consent, and the indemnified party may, at its own expense, participate in its defense of any claim. 
 (d) Sole Remedy. THE FOREGOING PROVISIONS OF THIS SECTION 12 STATE THE ENTIRE LIABILITY AND OBLIGATIONS OF EACH PARTY AND THE EXCLUSIVE REMEDY OF THE OTHER PARTY, WITH RESPECT TO ANY ALLEGED OR
ACTUAL INFRINGEMENT OF PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS OR OTHER INTELLECTUAL PROPERTY RIGHTS BY THE PRODUCTS. 
  

	13.	Term and Termination. 

 (a) Term. The term of
this Agreement shall commence on the Effective Date and expire six (6) months after the delivery of the fifty millionth Product (excluding Risk Wafers delivered pursuant to Sections 3(b) and 3(c)), unless earlier terminated as
provided herein. 
 (b) Termination. 
 (i) Delay of Product Acceptance. In the event that the Product Acceptance Date does not occur by December 31, 2005, this Agreement shall automatically terminate upon such date unless prior to such date the
parties agree (via written notice sent to the individuals specified in Section 15(g)) to extend the date by which the Product Acceptance must occur. If the parties so agree and the Product Acceptance does not occur by such extended date,
this Agreement shall automatically terminate on such extended date unless the parties otherwise agree to subsequently re-extend the date by which the Product Acceptance must occur. If this Agreement is terminated pursuant to this
Section 13(b)(i), Alien shall have no obligation to pay Impinj the Pre-Paid Amount or purchase the Minimum Purchase Amount. 
 (ii) For Cause. Either party may terminate this Agreement upon written notice in the event the other party materially breaches this Agreement and fails to cure such breach within thirty (30) days after the
date of written notice thereof by such party. 
 (iii) For Insolvency. Either party may terminate this Agreement by
written notice in the event: (1) the other party voluntarily enters into proceedings in bankruptcy or insolvency; (2) the other party makes an assignment for the benefit of creditors; (3) a petition is filed against the other party
under a bankruptcy law, a corporate reorganization law, or any other law for relief of debtors or similar law analogous in purpose or effect, which petition is not dismissed within one hundred and twenty (120) days of filing thereof; or
(4) the other party 

  

 19 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
enters into liquidation or dissolution proceedings or a receiver is appointed with respect to any assets of the other party, which appointment is not vacated
within one hundred and twenty (120) days. 
 (c) Effect of Termination. The following provisions shall survive any termination or
expiration of this Agreement: Sections 1, 4 (except for termination by Alien pursuant to Section 13(b)(i)), 5 (except for termination by Alien pursuant to Section 13(b)(i)), 9, 10,
11, 12, 13(c), 14 and 15. Nothing contained herein shall limit any other remedies that either party may have for the default of the other party under this Agreement nor relieve either party of any of its
obligations incurred prior to any expiration or termination of this Agreement. 
 (d) No Liability for Termination. Neither party
shall incur any liability or compensation obligation whatsoever for any damage (including and without limitation damage to or loss of goodwill or investment), loss or expenses of any kind suffered or incurred by the other party arising from or
relating to any termination of this Agreement pursuant to the terms hereof, whether or not such party is aware of any such loss or expenses. Termination is not the sole remedy and except as otherwise provided herein, all other remedies remain
available to each party. 
  

	14.	Limitation of Liability. 

 (a) EXCEPT FOR ANY BREACH
OF OR LIABILITY ARISING UNDER SECTIONS 10, OR 11, NEITHER PARTY SHALL BE LIABLE FOR INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHETHER SUCH DAMAGES ARE ALLEGED AS A RESULT OF TORTIOUS CONDUCT OR BREACH OF CONTRACT OR OTHERWISE, EVEN
IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. SUCH EXCLUDED DAMAGES SHALL INCLUDE BUT SHALL NOT BE LIMITED TO COST OF REMOVAL AND REINSTALLATION OF GOODS, LOSS OF GOODWILL, LOSS OF PROFITS, LOSS OF USE OF DATA, INTERRUPTION OF
BUSINESS OR OTHER ECONOMIC LOSS. REMEDIES PROVIDED HEREIN ARE INTENDED TO BE EXCLUSIVE (IN LIEU OF ANY OTHER REMEDY WHICH WOULD OTHERWISE HAVE BEEN AVAILABLE TO THE PARTIES AT LAW OR IN EQUITY). 
 (b) EXCEPT FOR ANY BREACH OF OR LIABILITY ARISING UNDER SECTIONS 4, 5(a), 10 OR 11, NEITHER PARTY’S TOTAL LIABILITY ARISING OUT OF OR
UNDER THIS AGREEMENT OR FOR BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED [***] THE TOTAL AMOUNTS PAID OR PAYABLE TO IMPINJ HEREUNDER.

 (c) EACH PARTY’S TOTAL LIABILITY ARISING OUT OF OR UNDER SECTION 4 OR FOR BREACH OF SECTION 4, WHETHER IN
CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED [***]. EACH PARTY’S TOTAL LIABILITY ARISING OUT OF OR UNDER SECTION 5(a) OR FOR BREACH OF
SECTION 5(a), WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION 

  

 20 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
NEGLIGENCE), STRICT LIABILITY OR ANY OTHER LEGAL THEORY, SHALL NOT EXCEED [***]. 
  

	15.	General. 

 (a) Governing Law; Venue. This
Agreement shall be governed by and construed under the laws of the State of California without regard to conflict of laws principles. The parties consent to the exclusive jurisdiction of, and venue in either Orange County, California, or Santa Clara
County, California, for any dispute arising out of or related to this Agreement. 
 (b) Assignment. Neither party shall transfer,
assign or delegate this Agreement or any rights or obligations hereunder, in whole or in part, whether voluntarily, by operation of law or otherwise, without the prior written consent of the other party, which consent shall not be unreasonably
withheld. Any purported transfer, assignment or delegation without such prior written consent will be null and void and of no force or effect. Notwithstanding the foregoing, each party shall have the right to assign this Agreement to any successor
to substantially all its business or assets to which this Agreement relates, whether by merger, sale of assets, sale of stock, reorganization or otherwise. Subject to the foregoing, this Agreement inures to the benefit of permitted successors and
assigns of each party. 
 (c) Waivers; Modification. No failure or delay (in whole or in part) by either party in exercising any
right, power, or remedy under this Agreement shall operate as a waiver of any such right, power, or remedy. No waiver or modification of any provision of this Agreement shall be effective unless in writing and signed by both parties. Any waiver by
either party of any provision of this Agreement shall not be construed as a waiver of any other provision or of such provision on any other occasion. 
 (d) Entire Agreement. Exhibits A and B are incorporated herein by this reference. This Agreement (including the Exhibits hereto) constitutes the entire agreement and understanding between the parties hereto
with respect to the subject matter hereof and supersedes any and all other agreements, written or oral, that the parties heretofore may have had with respect to the subject matter herein, including without limitation the term sheet signed by the
parties on May 20, 2005. 
 (e) Export. Each party agrees to fully comply with all applicable United States and foreign laws and
regulations with respect to the export, re-export, diversion or transfer of any products, technology, and information related to or exchanged under this Agreement, including without limitation the Export Administration Regulations issued by the
Department of Commerce, the International Trade Administration, and the Bureau of Export Administration, and the International Traffic in Arms Regulations (ITAR), including without limitation obtaining any necessary consents and requesting or filing
any documents. 
 (f) Severability. In the event any provision of this Agreement (or portion thereof, including the Exhibits hereto)
is determined by a court of competent jurisdiction to be invalid, illegal, or otherwise unenforceable, such provision shall be deemed to have been deleted from 

  

 21 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
this Agreement, while the remainder of this Agreement shall remain in full force and effect according to its terms. 
 (g) Notices. All notices permitted or required under this Agreement shall be in writing and shall be delivered in person, or by overnight delivery
service or by first class, registered or certified mail, postage prepaid, to the address of the party specified below or such other address as either party may specify in writing. Such notice shall be deemed to have been given upon delivery.

  

			
	 If to Impinj:
	  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Vinay Gokhale

	
	 With a required copy to:

		
		  	 Impinj, Inc.
 501 N. 34th Street, Suite 100

Seattle, WA 98103
 Attention: Legal Department

		
	 If to Alien:
	  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Thomas M.
Pounds

	
	With a required copy to:
		
		  	 Alien Technology Corporation
 18220 Butterfield
Blvd.
 Morgan Hill, CA 95037
 Attention: Legal
Department

 (h) Independent Contractors. The parties are independent contractors, and nothing in this
Agreement is intended to create any agency, partnership or joint venture relationship between them. 
 (i) Headings. The section
headings contained in this Agreement are included for convenience only, and shall not limit or otherwise affect the terms of this Agreement. 
 (j) Counterparts. This Agreement may be executed in any number of counterparts, and each executed counterpart shall have the same force and effect as an original instrument. 
 (k) Force Majeure. Neither party shall be responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its
reasonable control (other than payment of money), including but not limited to Acts of God, government actions, war, civil 

  

 22 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
disturbance, insurrection, sabotage, labor shortages or disputes, failure or delay in delivery by suppliers or subcontractors, transportation difficulties,
shortage of energy, raw materials or equipment, or the other party’s fault or negligence. In the event of any such delay the date of delivery shall, at the request of such party, be deferred for a period equal to the time lost by reason of the
delay. 
 [Signature Page Follows] 
  

 23 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the
Effective Date. 
  

									
	 Impinj:
	 		 	 Alien:

			
	 Impinj, Inc.
	 		 	 Alien Technology Corporation

					
	 By:
	 	 /s/ William T. Colleran
	 		 	 By:
	 	 /s/ John Payne

					
	 Name:
	 	 William T. Colleran
	 		 	 Name:
	 	 John Payne

					
	 Title:
	 	 President
	 		 	 Title:
	 	 Chief Operating Officer

  

 24 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit A 
 Monza Specifications 
 [***] 
  

 25 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing Procedures 
  

 26 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit B 
 Testing 
 This exhibit describes the test procedures currently employed by Impinj on Monza Products. This test
procedure can be modified with the mutual agreement of the parties. The Impinj patented Monza test procedure uses dedicated hardware and software to test each wafer with minimal test time and maximal coverage relative to a conventional approach. The
test procedure requires dedicated circuits placed in the scribe lanes (area that is consumed when die sawing is performed) that enable a bypass port that gives parallel access to all die in the reticle; this port is referred to as the Reticle Test
Interface (“RTI”), and consists of a die site with [***]. This circuit interfaces with an array of Die Test Interfaces (“DTI”), one for each chip in the reticle and adjacent to the chip it tests. A bus structure with redundant
elements for fault tolerance connects the single RTI with the many DTIs. 
 In a conventional wafer probe test, each die is independent and is tested via its
primary I/O ports. If applied to RFID projects, with tens of thousands of die per wafer, conventional wafer probe tests effectively have a single serial interface that operates at UHF frequencies. This leads to poor test coverage, very long test
times, and unforgiving hardware fixtures. 
 In contrast, the Impinj approach provides full wafer-probe testing at that is very cost effective, and at a high
level of coverage. Monza wafers have nearly [***] yieldable die sites (gross die per wafer, or GDPW), and after DTI testing, typically [***] are identified as good die (net die per wafer, or NDPW). This shows a raw yield of about [***], which is
slightly higher than the prediction of the fab yield model at [***], consistent with a robust design. DTI testing does not enable 100% fault detection, however, and our models for DPPM reduction predict a residual test escape rate of [***], or
[***]. Hence, outgoing quality levels rise to [***], and become the practical meaning of “known good die”. 
 For reference, a series of [***]
tests comprising digital functionality over the Gen2 command set, key analog parameters, and read+write pattern testing of the NVM, is performed on the wafer. All circuit blocks are tested with the exception of the rectifiers and parts of the modem,
since their operation depends on a microwave signal. This constitutes the majority of the residual [***] loss. This remaining factor can be dealt with by a minimal, and very fast, RF test after inlay assembly, which is needed in any event to
identify assembly losses. Note that the net yield of inlays or straps rises from an estimated [***] to [***] (for an assumed [***] assembly yield), or a factor of [***] reduction in scrap rates, as a result of this capability. 
  

 27 

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission.Master License Agreement between the registrant and Virage Logic, Inc.

 Exhibit 10.37 
  

			
	

	  	CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP.
		
		  	MASTER LICENSE AGREEMENT

 This Master License Agreement (“Agreement”) is made and entered into 24 September 2004
(“Effective Date”) by and between Virage Logic Corporation (“Virage Logic”), a Delaware corporation, with offices at 47100 Bayside Parkway, Fremont, California 94538 USA, and Alien Technology Corporation
(“Licensee”), a California corporation, with offices at 18220 Butterfield Boulevard, Morgan Hill, California 95037. 
 This
Agreement is a master license agreement that will govern the license of certain Virage Logic software products and other technology by Virage Logic to Licensee. Such licensed products and technology will be listed in schedule(s) (“Program
Schedule(s)”), that may be added hereto from time to time upon mutual execution of such Program Schedule(s). 
  

	1.	DEFINITIONS. 

 1.1. “Compiler”
means each Virage Logic development tool listed in a Program Schedule, which tool consists of: (i) object code versions of a set of executable software program(s), (ii) libraries containing design elements of memory cell arrays and control
logic, and (iii) all related documentation. Each Compiler includes any and all updates, replacements and enhancements thereto that Virage Logic delivers to the Licensee. 
 1.2. “Instance(s)” means designs of discrete integrated circuit memory cell arrays and corresponding control logic, which are either
generated for Licensee by Virage Logic and described in a Program Schedule, or are generated by Licensee through the use of a Compiler licensed hereunder. Instances will be expressed in GDSII, and such other hardware definition languages or other
formats as are agreed by the parties in writing. Each Instance includes all documentation related to the design and any and all updates, replacements and enhancements thereto that Virage Logic delivers to the Licensee. 
 1.3. “Licensed Material(s)” means, collectively, the Compiler(s) licensed hereunder, if any, Instance(s) generated by Licensee on any
Compiler licensed hereunder or generated for Licensee by Virage Logic, Standard Cells, Metal Programmable Cells, I/Os, and NXT Technology, and such other deliverables that Virage Logic delivers to the Licensee. 
 1.4. “Intellectual Property Rights” means worldwide common law and statutory rights associated with patent rights (including patent
applications and disclosures), rights of priority, works of authorship, mask work rights, copyrights (including copyright applications and registrations), moral rights, trade and industrial secrets, know-how and any other intellectual property
rights recognized in any country or jurisdiction of the world, including divisions, continuations, renewals, reissuances and extensions of each now existing or hereafter filed, issued or acquired; exclusive of the Marks. 
 1.5. “I/O” means integrated circuit off-chip interface component available in a variety of functional and electrical characteristics as
well as physical implementations. 
 1.6. “Marks” means trademarks, trade names, logos, service marks, and other
designations of source. 
 1.7. “NXT Technology” means all of the Intellectual Property Rights owned by Virage Logic on the
Effective Date related to Standard Cell and Metal Programmable Cell architecture and routing methodologies, including, but not limited to, US patents 5,723,883; 5,898,194; 5,923,059; 5,923,060; and 6,091,090. 
  

					
	Master License Agreement	  		  	 Page
 1

	Rev. 12/2002	  		  	Confidential

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 1.8. “Standard Cell” means a type of integrated circuit logic function element,
specifically designed for automated place and route tools, and where the logic functionality of the cell is altered by metal as well as gate and diffusion layers. It has common physical architecture attributes for all functional elements in the
Standard Cell library. 
 1.9. “Metal Programmable Cell” means a type of integrated circuit logic function element,
specifically designed for automated place and route tools, and where the logic functionality of the cell is altered by metal layers only, with common gate and diffusion layers. It has common physical architecture attributes for all functional
elements in the Metal Programmable Cell library. 
 1.10 “Acceptance Requirements” means the Specifications, against which
Licensee will test conformance of the deliverables. 
 1.11 “Statement of Work” means the development plan, including
deliverables and associated milestones, and the development schedule, as set forth in Attachment 1 to the pertinent Program Schedule. 
 1.12
“Specifications” means the functional, operational and performance requirements for the technology set forth in Attachment 2 to the pertinent Program Schedule. 
  

	2.	LICENSE GRANTS. 

 2.1. License Grants. Virage
Logic hereby grants to Licensee, subject to the terms and conditions of this Agreement and the restrictions set forth in the pertinent Program Schedule(s), under Virage Logic’s Intellectual Property Rights, a non-exclusive, non-transferable
fee-bearing license to: 
 (a) use each Compiler licensed hereunder to create Instances; 
 (b) use, copy and reproduce Instances licensed hereunder (whether generated by Licensee or by Virage Logic on Licensee’s behalf)
solely to design and develop Licensee’s integrated circuits; 
 (c) distribute such Instances solely: (i) in GDSII
data format to the semiconductor manufacturer set forth for the relevant Licensed Materials in the pertinent Program Schedule(s) and solely for the purpose of enabling such manufacturer(s) to manufacture integrated circuits for Licensee, and
(ii) as incorporated into physical implementations of Licensee’s integrated circuits as reduced to silicon; and 
 (d) make, have made, use, sell, offer to sell, import and export integrated circuits that include the Licensed Materials. 
 2.2.
Limitations on Licenses. 
 (a) Licensee may use Licensed Materials, subject to any and all restrictions set forth in
the pertinent Program Schedule(s), only for the applications and processes set forth for those Licensed Materials in the pertinent Program Schedule(s). 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 2
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (b) Licensee has no right to transfer, sublicense, or otherwise distribute Licensed
Materials except as expressly set forth in this Agreement and the pertinent Program Schedule(s), and without limiting the generality of the foregoing, information (including, but not limited to GDSII data) that reflects any element of Licensed
Materials may be provided only to the semiconductor manufacturer(s) set forth for the relevant Licensed Materials in the pertinent Program Schedule(s) and solely for the purpose of enabling such manufacturer to manufacture integrated circuits for
Licensee and for the sale of such integrated circuits through Licensee’s multi-tiered distribution and sales network. 
 (c) Licensee will not: (i) copy or otherwise reproduce any Licensed Materials, in whole or in part, except as expressly authorized by this Agreement and the pertinent Program Schedule(s) or to make more than reasonable numbers of
back-up copies; (ii) modify the Licensed Materials; or (iii) use the Licensed Materials in any manner to provide services to third parties, including, but not limited to, integrated circuit design services (provided, however, that such
services restriction will not prevent Licensee from providing services that bundle integrated circuits that include Licensed Materials). 
 (d) Licensee’s rights in the Licensed Materials will be limited to those expressly granted in this Agreement and pertinent Program Schedule(s), and Virage Logic reserves all its rights and licenses not
expressly granted to Licensee in this Agreement. 
 2.3 Notification of Semiconductor Manufacturer Tape Outs. 
 In the event a semiconductor manufacturer is manufacturing integrated circuits for Licensee as authorized by the pertinent Program
Schedule(s), Licensee agrees to provide to Virage Logic, no more frequently than quarterly, a report via email addressed to tapeout@viragelogic.com setting forth the project tracking number used by the semiconductor manufacturer to identify
tape outs, and if applicable, the number of wafers (that include integrated circuits that include an Instance) manufactured using the Licensed Materials authorized by this Agreement and the pertinent Program Schedule(s). 
  

	3.	PROPRIETARY RIGHTS. 

 (a) As between the parties to this Agreement, to the extent ownership is vested in such parties, the Licensed Materials are and will remain the sole and exclusive property of Virage Logic and its suppliers, if any,
whether the Licensed Materials are separate or combined with any other products. Virage Logic’s rights under this subsection (a) will include, but not be limited to, all copies of the Licensed Materials, in whole and in part; and all
Intellectual Property Rights in the Licensed Materials. 
 (b) Licensee will not delete or in any manner alter the Marks
notices of Virage Logic and its suppliers, if any, appearing on the Licensed Materials as delivered to Licensee. As a condition of the license rights granted to Licensee in this Agreement, Licensee will reproduce and display such notices on each
copy it makes of any Licensed Material. 
 (c) Nothing in this Agreement grants to either party any rights in or to use any of
the Marks of the other party, except to the limited extent necessary for Licensee to reproduce such Marks in accordance with this Agreement. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 3
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (d) Licensee agrees to declare, to the semiconductor manufacturer that manufactures
wafers as permitted hereby, Virage Logic as a licensor of certain intellectual property embodied in the Licensed Materials that is contained in Licensee’s products as produced by the semiconductor manufacturer authorized by the pertinent
Program Schedule(s). Licensee agrees to execute such reasonable declaration as provided by the semiconductor manufacturer to document the content of the Licensed Materials in Licensee’s products. Upon Virage Logic’s request, Licensee
agrees to authorize the applicable semiconductor manufacturer to provide information directly to Virage Logic documenting the content of the Licensed Materials in Licensee’s products. 
 (e) Licensee acknowledges and agrees that all output generated for Licensee by Virage Logic as described in the pertinent Program
Schedule(s), or generated by Licensee through use of any Compiler licensed hereunder contains information that complies with the Virtual Component Identification Physical Tagging Standard (VCID) as maintained by the Virtual Socket Interface Alliance
(VSIA). Such information may be expressed in GDSII Layer 63 or other such layer designated by the VSIA, hardware definition languages, or other formats. Licensee is not authorized to alter or change any such information. 
  

	4.	PAYMENT; TAXES. 

 Licensee will pay Virage Logic the
amount(s) due as set forth in the pertinent Program Schedule(s) in accordance with the terms of such Program Schedule(s). Thirty days following notice by Virage Logic of any delinquency by Licensee in its payment obligations, payments will incur
interest at a rate equal to 1.0% per month or the highest rate permitted by applicable law, whichever is lower. All amount(s) due and other charges stated herein are exclusive of any sales, use, value-added, or other federal, state or local
taxes (excluding taxes based on Virage Logic’s net income) and Licensee agrees to pay such taxes. 
  

	5.	CONFIDENTIALITY. 

 5.1. Confidential
Information. “Confidential Information” means: (i) for Virage Logic, the Licensed Materials; (ii) for Licensee, information about Licensee’s products that include the Licensed Materials; and (iii) any business or technical
information of Virage Logic or Licensee, that is clearly designated by the discloser as “confidential” or “proprietary” and, if orally or visually disclosed, identified as “confidential” or “proprietary” at
the time of such disclosure and summarized in writing by the discloser and transmitted to the recipient within thirty (30) days of such disclosure. 
 5.2. Exclusions. Confidential Information shall not include information that the recipient can document: (i) is or becomes generally known or available by publication, commercial use or otherwise through no fault of the
recipient; (ii) is known to the recipient at the time of disclosure without violation of any confidentiality restriction and without any restriction on the receiving party’s further use or disclosure; (iii) is independently developed
by the recipient; (iv) was received from a third party rightfully in possession of such information without an obligation of confidentiality; (v) is permitted for release or disclosure to any third party by the written prior consent of the
discloser; (vi) is intentionally furnished to a third party by the discloser without imposing confidentiality restrictions on such third party; or (vii) as permitted in a Program Schedule. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 4
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 5.3. Use and Disclosure Restrictions. For a term of three (3) years from the last
disclosure of Confidential Information, each party will refrain from using the other party’s Confidential Information except as permitted herein, and will use the same level of care, but in any event will not use less than reasonable care, to
prevent disclosure of the other party’s Confidential Information that it uses with its own information of similar sensitivity and importance. However, each party may disclose Confidential Information of the other party: (i) pursuant to the
order or requirement of a court, administrative agency, or other governmental body, provided that the disclosing party gives reasonable notice to the other party to contest such order or requirement; and (ii) on a confidential basis to
contractors, or legal or financial advisors who are under obligations no less restrictive than those contained herein regarding confidentiality and use. Notwithstanding anything herein, provided that such direct competitor has been identified to
Licensee by Virage Logic in writing, Licensee will not allow any individual who is an employee or agent of a direct competitor of Virage Logic to have access to the Licensed Materials or Virage Logic’s Confidential Information. 
  

	6.	WARRANTY. 

 6.1 Power and Authority. Each
party warrants to the other that it has sufficient corporate power and authority to enter into this Agreement and to grant to the other all licenses and rights that it grants under this Agreement. 
 6.2 No Reverse Engineering. In order to protect the trade secrets and other proprietary information of Virage Logic, Licensee warrants that,
except as expressly permitted under applicable law, it will not reverse engineer, disassemble, or otherwise attempt to derive the source code form of the Licensed Materials. 
 6.3 Conformance. Except as otherwise provided in a Program Schedule, Virage Logic warrants, for a period of ninety (90) days from the date
Virage Logic delivers the Licensed Materials to Licensee, , that the Licensed Materials will substantially and materially conform to the Specifications. The foregoing warranty does not apply to any element of the Licensed Materials that has been
modified outside the Specifications or used outside the Specifications as set forth in the applicable Program Schedule. 
 6.4 Sole and
Exclusive Remedy. LICENSEE’S SOLE AND EXCLUSIVE REMEDY WILL BE THAT VIRAGE LOGIC WILL, AT VIRAGE LOGIC’S OPTION, EITHER REPLACE OR CORRECT THE DEFECTIVE PORTION OF THE LICENSED MATERIALS WITHIN THIRTY (30) DAYS OF BEING INFORMED
OF THE BREACH OF WARRANTY. 
 6.5 Disclaimer of Other Warranties. THE WARRANTIES IN THIS SECTION ARE IN LIEU OF ALL OTHER WARRANTIES,
EXPRESS AND IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, VIRAGE LOGIC DOES NOT WARRANT THAT THE LICENSED
MATERIALS WILL MEET LICENSEE’S REQUIREMENTS, THAT THE LICENSED MATERIALS WILL OPERATE IN THE COMBINATIONS THAT LICENSEE MAY SELECT OR USE, THAT THE OPERATION OF THE LICENSED MATERIALS WILL BE UNINTERRUPTED OR ERROR FREE. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 5
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

	7.	INDEMNITIES. 

 7.1. Indemnity. Subject to the
terms of Sections 7.1 and 7.2, Licensee agrees to indemnify Virage Logic against any third party claims against Virage Logic for loss, damage, liability, or expense (including but not limited to attorneys’ fees) arising out of any damage to
tangible property or personal injuries caused by the negligent acts or omissions of Licensee in connection with Licensee’s activities under this Agreement. Virage Logic agrees to indemnify Licensee against any third party claims against
Licensee for loss, damage, liability, or expense (including but not limited to attorneys’ fees) arising out of any damage to tangible property or personal injuries caused by the negligent acts or omissions of Virage Logic in connection with
Virage Logic’s activities under this Agreement. 
 7.2. Infringement Indemnity. 
 (a) Duty to Indemnify and Defend. Virage Logic will indemnify Licensee against, and will defend or settle at Virage Logic’s
own expense any claim made or action or other proceeding brought against Licensee (i) to the extent that it is based on a claim that Virage Logic has infringed a U.S., European Union, Japan, South Korea, Republic of China (Taiwan), or Canada
patent or has misappropriated or any other third party Intellectual Property Rights and/or Marks which caused damage to Licensee or any third party. Virage Logic will pay costs, damages, and expenses (including reasonable attorneys’ fees and
costs) incurred by Licensee in any such action or proceeding or otherwise attributable to any such claim. Virage Logic will have no obligation under this Section as to any action, proceeding, or claim unless: (i) Virage Logic is notified of it
promptly; (ii) Virage Logic has sole control of its defense and settlement; and (iii) Licensee provides Virage Logic with reasonable assistance in its defense and settlement. 
 (b) Injunctions. If Licensee’s use of any Licensed Materials under the terms of this Agreement is, or in Virage Logic’s
reasonable opinion is likely to be, enjoined due to the type of infringement or misappropriation specified in subsection (a) above, then Virage Logic shall, at its sole option and expense, either: (i) procure for Licensee the right to
continue using such Licensed Materials under the terms of this Agreement; or (ii) replace or modify such Licensed Materials so that they are noninfringing and substantially equivalent in function to the infringing or misappropriating Licensed
Materials. If (i) or (ii) are not reasonably possible or are technically infeasible, respectively, Virage Logic shall so notify Licensee in writing and Licensee may elect, at Licensee’s sole option, either to: (a) relinquish
Licensee’s license to use such Licensed Materials and Virage Logic shall fully refund to Licensee any amount paid hereunder (including prepaid royalties), less a reasonable amount for prior use, for the infringing or misappropriating Licensed
Materials, or (b) continue to use the Licensed Materials; provided that Virage Logic shall have no further obligation to indemnify and defend Licensee following Licensee’s use or distribution of the Licensed Materials beyond six
(6) months after the date of such notice. 
 (c) Sole Remedy. THE FOREGOING ARE VIRAGE LOGIC’S SOLE AND
EXCLUSIVE OBLIGATIONS, AND LICENSEE’S SOLE AND EXCLUSIVE REMEDIES, WITH RESPECT TO INFRINGEMENT OR MISAPPROPRIATION OF INTELLECTUAL PROPERTY RIGHTS. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 6
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 (d) Exclusions. Virage Logic will have no obligations under this
Section 7.2 with respect to infringement or misappropriation arising from: (i) modifications to the Licensed Materials by any party other than Virage Logic, (ii) changes to Licensed Material specifications requested by Licensee,
(iii) any Instances generated by Licensee except to the extent such infringement or misappropriation existed in the applicable Compiler as provided to Licensee, or (iv) the use of the Licensed Materials in combination with products or
technology not provided by Virage Logic if the claim would not have occurred but for the combination. 
  

	8.	TERM AND TERMINATION. 

 8.1. Term. The term
of this Agreement will begin on the Effective Date and will continue, unless terminated earlier in accordance with the provisions of Section 8.2 below, for the period specified in the pertinent Program Schedule(s) for the Licensed Materials
solely for the applications and processes specified therein. 
 8.2. Events of Termination. 
 (a) Either party will have the right to terminate this Agreement if: (i) the other party breaches any material term or condition of
this Agreement and fails to cure such breach within thirty (30) days after written notice or in the event the nature of such breach is such that it cannot be cured within thirty (30) days then such party shall not be in breach if it
immediately commences to cure such breach and prosecutes such cure until completion; (ii) the other party becomes the subject of a voluntary petition in bankruptcy or any voluntary proceeding relating to insolvency, receivership, liquidation,
or composition for the benefit of creditors; or (iii) the other party becomes the subject of an involuntary petition in bankruptcy or any involuntary proceeding relating to insolvency, receivership, liquidation, or composition for the benefit
of creditors, if such petition or proceeding is not dismissed within sixty (60) days of filing. 
 (b) Virage Logic will
have the right to terminate this Agreement if Licensee acquires, consolidates or merges with a direct competitor of Virage Logic. For the purposes of this Agreement, Exhibit A to the Agreement is an exhaustive list of direct competitors of Virage
Logic as of the Effective Date. Virage Logic may update Exhibit A in writing, and such update shall be effective thirty (30) days after receipt of such notice by Licensee.). 
 8.3. Effect of Termination. Upon termination or expiration of this Agreement, Licensee will immediately return to Virage Logic or (at Virage
Logic’s request) destroy all copies of the Licensed Materials and each party will immediately return the other party’s Confidential Information in its possession or control, and an officer of each party will certify to the other party in
writing that such party has done so. For those integrated circuits for which manufacturing has already commenced, Licensee will have the right to continue to use the Licensed Materials, subject to the terms of Section 2.1 and the restrictions
of the pertinent Program Schedule(s), for which Licensee has paid or has a duty to pay amount(s) due as of the effective date of the termination. 
 8.4. No Damages for Termination. Neither party will be liable to the other on account of termination or expiration of this Agreement for reimbursement or damages for the loss of goodwill, prospective profits or anticipated income, or
on account of any expenditures, investments, leases or 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 7
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
commitments made by either party or for any other reason whatsoever based upon or growing out of such termination or expiration. 
 8.5. Nonexclusive Remedy. The exercise by either party of any remedy under this Agreement will be without prejudice to its other remedies
under this Agreement or otherwise. 
 8.6. Survival. The rights and obligations of the parties contained in Sections 1, 2.1 (to the
limited extent permitted by Section 8.3), 2.2, 2.3, 3, 4, 5, 6, 7, 8.3, 8.4, 8.5, 8.6, 9, and 10 will survive the termination or expiration of this Agreement. 
  

	9.	LIMITATIONS OF LIABILITY. 

 9.1. Limitations.

 (a) Licensee Limitations. 
 (i) IN NO EVENT WILL LICENSEE BE LIABLE FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCT LIABILITY, INFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS OR OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. 
 (ii) TO THE EXTENT
NOT PROHIBITED BY APPLICABLE LAW, LICENSEE’S TOTAL LIABILITY UNDER THIS AGREEMENT WILL BE LIMITED TO AN AMOUNT EQUAL TO THE DEVELOPMENT AND LICENSE AND MAINTENANCE FEES OWING BY LICENSEE TO VIRAGE LOGIC UNDER THIS AGREEMENT. 
 (b) Virage Logic Limitations. 
 (i) IN NO EVENT WILL VIRAGE LOGIC BE LIABLE FOR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), PRODUCT LIABILITY, INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OR
OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. 
 (ii) EXCEPT FOR DAMAGES
ARISING PURSUANT TO SECTIONS 5 AND 7, AND TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW, VIRAGE LOGIC’S TOTAL LIABILITY TO LICENSEE WILL BE LIMITED TO THE DEVELOPMENT, LICENSE AND MAINTENANCE FEES RECEIVED BY VIRAGE LOGIC FROM LICENSEE UNDER
THIS AGREEMENT. 
 (iii) FOR DAMAGES ARISING PURSUANT TO SECTIONS 5 AND 7, AND TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW,
VIRAGE LOGIC’S TOTAL LIABILITY TO LICENSEE UNDER THIS AGREEMENT WILL BE LIMITED TO AN AMOUNT EQUAL TO TWO TIMES (2X) THE DEVELOPMENT, LICENSE, AND MAINTENANCE FEES RECEIVED BY VIRAGE LOGIC FROM LICENSEE UNDER THIS AGREEMENT. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 8
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 9.2. Failure of Essential Purpose. The parties have agreed that the limitations specified in
this Section 9 will survive and apply even if any limited remedy specified in this Agreement is found to have failed of its essential purpose. 
  

	10.	GENERAL. 

 10.1 Compliance with Law. Each
party agrees to comply with all applicable laws, rules, and regulations in connection with its activities under this Agreement. Each party shall comply with all applicable international, national, state, regional and local laws and regulations in
connection with its activities under this Agreement. Without limiting the foregoing, Licensee acknowledges that all Licensed Materials, including documentation and other Virage Logic technical data, may be subject to export controls imposed by the
U.S. Export Administration Act of 1979, as amended (the “Act”), and the regulations promulgated thereunder. Licensee shall not export or re-export (directly or indirectly) any Licensed Materials or other Virage Logic technical data
therefor without complying with the Act and the regulations thereunder. 
 10.2 Publicity. Upon Licensee’s first sale of
commercial quantities of Licensee’s products that include integrated circuits manufactured (and which include the Licensed Materials) in accordance with a Program Schedule, Virage Logic may include Licensee’s name in Virage Logic’s
customer list. Licensee agrees to provide Virage Logic with written notice (including email form) of such first sale of commercial quantities of Licensee’s products and respond to Virage Logic’s reasonable inquires concerning such first
sale. Neither party shall disclose the existence or the terms and conditions of this Agreement to any third party, except as may be required (i) to implement or enforce the terms of this Agreement; (ii) by legal procedure or by law; or
(iii) by an existing or potential investor, acquiring company, bank or other financial institution, under appropriate non-disclosure terms in connection with a merger, acquisition, financing, loan agreement, or similar corporate transaction.
Virage Logic shall not, without first obtaining the prior written consent of Licensee, announce this Agreement in a press release, to customers, or potential customers of Virage Logic or in or as part of other promotional material. 
 10.3. Assignment. This Agreement will bind and inure to the benefit of each party’s permitted successors and assigns. Except as permitted in
this Section 10.3, neither party may not assign this Agreement either voluntarily, by merger, by operation of law or otherwise in whole or in part, without the other party’s written consent, which consent will not be unreasonably withheld.
Except as permitted in this Section 10.3, any attempt to assign this Agreement without such consent will be null and void. Should it be necessary for this Agreement to be assigned to a third party in connection with that party’s
acquisition of Virage Logic, Licensee hereby agrees in advance to the assignment. Licensee may assign (i) this Agreement to an Licensee affiliate, or (ii) this Agreement in the event of a merger, acquisition, reorganization or sale of all
or substantially all of the assets of Licensee, subject to the provisions of Section 8.2(b). 
 10.4. Governing Law. This
Agreement will be governed by and construed in accordance with the laws of the State of California without regard to its conflict of law principles and applicable to agreements entered into, and to be performed entirely, within California between
California residents. Any suit hereunder will be brought solely in the federal or state courts in the Northern District of California and each party hereby submits to the personal jurisdiction thereof. 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 9
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 10.5. Injunctive Relief. 
 (a) Licensee acknowledges that the Licensed Materials contain and embody trade secrets and other intellectual property of Virage Logic, the disclosure or
unauthorized use of which would cause substantial harm to Virage Logic that could not be remedied by the payment of damages alone. Accordingly, Virage Logic will be entitled to seek preliminary and permanent injunctive relief and other equitable
relief for any breach of Licensee’s obligations of confidentiality or use of Licensed Materials not in accordance with this Agreement. 
 (b) Virage Logic acknowledges that the Licensee’s confidential information contains and embodies trade secrets and other intellectual property of Licensee, the disclosure or unauthorized use of which would cause substantial harm to
Licensee that could not be remedied by the payment of damages alone. Accordingly, Licensee will be entitled to seek preliminary and permanent injunctive relief and other equitable relief for any breach of Virage Logic’s obligations of
confidentiality or use of Licensee’s confidential information not in accordance with this Agreement. 
 10.6. Severability. If
any provision of this Agreement is found invalid or unenforceable, that provision will be enforced to the maximum extent permissible, and the other provisions of this Agreement will remain in force. 
 10.7. Force Majeure. Except for payments due under this Agreement, neither party will be responsible for any failure to perform due to acts of
God, war, riot, embargoes, acts of civil or military authorities, fire, floods, earthquakes, or accidents caused by third parties not under the control of a party (each a “Force Majeure”), provided that such party gives prompt
written notice thereof to the other party. The time for performance will be extended for a period equal to the duration of the Force Majeure, but in no event longer than thirty (30) days. 
 10.8. Notices. All notices under this Agreement will be deemed given when delivered personally, sent by confirmed facsimile transmission, or sent
by certified or registered U.S. mail or nationally-recognized express courier, return receipt requested, to the address shown below or as may otherwise be specified by either party to the other in accordance with this Section. Notices to Licensee
must be also addressed “Attention: General Counsel.” 
 10.9. Independent Contractors. The parties to this Agreement are
independent contractors. There is no relationship of partnership, joint venture, employment, franchise, or agency between the parties. Neither party will have the power to bind the other or incur obligations on the other’s behalf without the
other’s prior written consent. 
 10.10. Waiver. No failure of either party to exercise or enforce any of its rights under this
Agreement will act as a waiver of such rights. 
 10.11. Entire Agreement. This Agreement and its Program Schedule(s), attachments,
and exhibits are the complete and exclusive agreement between the parties with respect to the subject matter hereof, superseding and replacing any and all prior agreements, communications, and understandings (both written and oral) regarding such
subject matter. This Agreement may only be modified, or any 

  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 10
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 
rights under it waived, by a written document expressly referring to an amendment of this Agreement and executed by both parties. 
 10.12 Counterparts. This Agreement may be signed in one or more counterparts, each of which will be deemed to be an original and all of which when
taken together will constitute the same agreement. If this Agreement is executed in counterparts, no signatory hereto shall be bound until both Parties named below have duly executed or caused to be duly executed a counterpart of this Agreement. Any
copy of this Agreement made by reliable means is considered an original. 
 10.13 Order of Precedence. Where in conflict, the terms of
the pertinent Program Schedule shall take precedence over the terms of this Agreement. 
 IN WITNESS WHEREOF, the parties have caused this
Agreement to be executed by their duly-authorized representatives as of the Effective Date. 
  

									
	 Licensee: Alien Technology Corporation
	 		 	Virage Logic Corporation
					
	 By:
	 	 /S/    JOHN PAYNE
	 		 	 By:
	 	 /S/    ADAM
KABLANIAN

	 Name:
	 	 John Payne
	 		 	 Name:
	 	 Adam Kablanian

	 Title:
	 	 COO
	 		 	 Title:
	 	 President & CEO

					
	 Address:
	 	 18220 Butterfield Boulevard
 Morgan Hill, California 95037
	 		 	 Address:
	 	 47100 Bayside Parkway
 Fremont, California 94538 USA

					
	 Facsimile:
	 	 408-732-3910
	 		 	 Facsimile:
	 	 510-360-8099

 The following exhibit is hereby incorporated into this Agreement: 
 Exhibit A – List of Virage Logic Direct Competitors 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 11
	Rev. 10/2002	  		  	Confidential

 CONFIDENTIAL TREATMENT REQUESTED BY ALIEN TECHNOLOGY CORP. 
  

 Exhibit A – List of Virage Logic Direct Competitors 
 [***] 
  

	***	Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with
the Commission. 

  

					
	Master License Agreement	  		  	Page 12
	Rev. 10/2002	  		  	Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]